Navigation Links
PDL BioPharma to Present at the 25th Annual Piper Jaffray Healthcare Conference

INCLINE VILLAGE, Nev., Dec. 2, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference in New York tomorrow, Tuesday, December 3, 2013 at 3:00 p.m. Eastern Time.


This presentation will be available to interested parties through a live and archived audio webcast. To access the live and subsequently archived webcast of the presentation, go to the Company's website at and go to "Events and Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. The archived webcast will be available for seven days following the presentation.

About PDL BioPharma, Inc.
PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue. PDL is currently focused on intellectual property asset management, investing in new income generating assets, and maximizing value for its shareholders.

The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada.

In 2011, PDL initiated a strategy to bring in new income generating assets from the healthcare sector. To accomplish this goal, PDL seeks to provide non-dilutive growth capital and financing solutions to late stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL successfully executed on this strategy by deploying approximately $500 million to date and continues to pursue this strategic initiative. PDL is focused on the quality of the income generating assets and potential returns on investment.

For more information, please visit

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
2. IPO, Earnings & Corporate Developments: Twitter, Vale SA, OCZ Technology Group, Radian Group, Keryx Biopharmaceuticals
3. TransCelerate BioPharma Inc. Launches Second Year Initiatives, Expands Membership and Achieves Milestones for Original Projects
4. Biopharmaceuticals - A Global Market Overview
5. Can-Fite BioPharma to Conduct European Road Show
6. MGB Biopharma to Present at Bio-Europe 2013
7. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
8. PDL BioPharma to Announce Third Quarter 2013 Financial Results on November 6, 2013
9. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
10. Bright Future Ahead for Biopharmaceutical Contract Manufacturing, Says Frost & Sullivan
11. Enteris BioPharma and Nordic BioSciences KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris Proprietary Oral Drug Delivery and Manufacturing Platform
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... a new closed system for isolating adipose-derived stem cells. The announcement starts a new ... adipose tissue. SVF is a component of the lipoaspirate obtained from liposuction of excess ...
(Date:11/30/2015)...  An interventional radiology technique shows promise for helping morbidly ... a study being presented today at the annual meeting of ... (RSNA). --> --> ... radiologists as a way to stop bleeding in emergency situations, ... of treating obesity is new. Mubin Syed , ...
(Date:11/30/2015)... ALBANY, N.Y. , Nov. 30, 2015 /PRNewswire-USNewswire/ ... led by assistant chemistry professor Jan Halámek, is ... level.   --> ...   --> ... researchers at UAlbany have discovered a straightforward concept ...
(Date:11/30/2015)... 30, 2015 Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... initiatives designed to create shareholder value. ... Spherix. "Based on published reports, the total addressable ... billion and Spherix will seek to secure fair ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
Breaking Biology News(10 mins):